FDA

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

FDA
Sep 15, 2024, 15:58 | Blog
OncoInfluencers to Follow on Social Media: Dr. Neeraj Agarwal
We are delighted to feature Dr. Neeraj Agarwal as a key figure in the oncology…
Sep 13, 2024, 19:19 | Blog
Advances in cancer care must consider the impact on patients’ reproductive health - ASCO
ASCO - American Society of Clinical Oncology made the following post on LinkedIn: “Advances in cancer care…
Sep 10, 2024, 10:28 | Blog
Matthew Herper: Facing cancer is hard -- even if you're someone who would change the way we treat cancer
Matthew Herper, Senior Writer, Medicine, and Editorial Director, Events at STAT, made the following post…
Sep 9, 2024, 13:41 | Dialogues
Dr. Vivek Subbiah on Pioneering Precision Oncology and Global Clinical Trials | OncoInfluencers #13
Dr. Vivek Subbiah, Chief of Early Phase Drug Development at Sarah Cannon Research Institute, joins…
Sep 4, 2024, 11:43 | Blog
Rochelle G Prosser: I am excited to speak about Precision Oncology at the FNIH's Team Science Day
Orchid Healthcare Solutions shared a post by Rochelle G Prosser, Founder, CEO at Orchid Healthcare…
Sep 3, 2024, 13:39 | Blog
Herbert Loong: A very important resource for oncology drug developers globally
Herbert Loong shared a post on X: "A very important resource for oncology drug developers globally.…
Sep 2, 2024, 19:15 | Insight
Patrick Hwu: How does anti-CTLA-4 and anti-PD-1 combination work mechanistically?
Patrick Hwu shared a post on LinkedIn: “The combination of anti-CTLA-4 and anti-PD-1 antibodies is…
Sep 2, 2024, 07:22 | Blog
Chris Hourigan: Build your cancer research program at the new Virginia Tech Fralin Biomedical Research Institute Cancer Research Center
Chris Hourigan, Director, Virginia Tech FBRI Cancer Research Center (DC), Virginia Tech shared a post…
Sep 1, 2024, 16:37 | Blog
Advancements in Medical Treatments, Neuroscience, and the Power of Metals - The Babak Lab
 The Babak Lab shared a post on LinkedIn: ''Weekly Digest: Advancements in Medical Treatments, Neuroscience,…
Sep 1, 2024, 16:26 | Blog
Vivek Subbiah: Clinical trial vs fiction
Vivek Subbiah shared an article on LinkedIn: ''Every single drug, medicine, and treatment you’ve ever…
Aug 31, 2024, 14:15 | Insight
Tumour-agnostic authorised indications by FDA and EMA
Elisa Agostinetto shared a post on X about a recent paper by Benedikt Westphalen et…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 28, 2024, 17:09 | Blog
Tanja Obradovic: Importance of vigilant toxicity monitoring
Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…
Aug 27, 2024, 22:42 | Drugs
Maria Babak: Approval of axatilimab-csfr is a significant development in the treatment of cGVHD
Maria Babak shared a post by The Babak Lab on LinkedIn: "This is a significant…
Aug 26, 2024, 19:50 | Blog
Tanja Obradovic reflects on first KRAS G12C mutation inhibitor approval
Tanja Obradovic posted on LinkedIn: "First KRAS G12C mutation inhibitor just got approval in China.…
Aug 25, 2024, 16:32 | Blog
Francisco J. Esteva: Capivasertib combined with fulvestrant offers new hope in breast cancer
Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital shared a…
Aug 24, 2024, 11:47 | Insight
Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial
Narjust Florez shared a post by IASLC on X, adding: “At The International Association for…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 24, 2024, 10:51 | Insight
Shahrin Ahmed: High health care utilization and poor survival rate in older adults with AML
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: “Older…
Aug 23, 2024, 17:15 | Blog
Brian Shields: AI evaluates recent FDA decision
Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn: "AI evaluates recent FDA decision:…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 23, 2024, 14:20 | Blog
FDA Approves Johnson & Johnson's Chemotherapy-Free Regimen for EGFR-Mutated Lung Cancer
Kiran Patel, Vice President of Clinical Development in Solid Tumor Franchise at The Janssen Pharmaceutical…
Aug 21, 2024, 14:03 | Blog
$3 million research grant to Dana-Farber Cancer Institute and UT Health San Antonio to study BRCA therapy
Dana-Farber Cancer Institute shared on LinkedIn: "Scientists at Dana-Farber's Center for BRCA and Related Genes in…
Aug 21, 2024, 13:57 | Blog
AACR - Broadening eligibility criteria for cancer clinical trials may better demonstrate how a drug will affect a real-world population
American Association for Cancer Research shared on LinkedIn: "Broadening eligibility criteria for cancer clinical trials allows…
Aug 20, 2024, 14:50 | Drugs
Key takeaways from the FDA approval of dostarlimab-gxly in endometrial cancer - The Babak Lab
The Babak Lab shared on LinkedIn: "FDA Expands Endometrial Cancer Treatment: The FDA has approved…
Aug 20, 2024, 10:46 | Insight
Houman Sotoudeh: MRI Math, AI Platform-Cyber Device for GBM is now FDA-approved
Houman Sotoudeh, Associate Professor of Neuroradiology and Neurology at University of Alabama at Birmingham, shared…
Aug 17, 2024, 09:13 | Positive
Harpreet Singh: Exciting news in colorectal cancer treatment
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn: "Exciting…
Aug 16, 2024, 18:50 | Blog
Kai Chen received the 1st place student paper award from the ASA Biopharmaceutical Section
Kai Chen shared a post on LinkedIn: "It is a great honor to receive the…
Aug 14, 2024, 18:31 | Blog
Jennifer Bires about FDA’s recent decision on MDMA
Jennifer Bires, Executive Director of Life with Cancer and Patient Experience at Inova Schar Cancer…
Aug 14, 2024, 15:35 | Blog
Vincent Rajkumar: Updated Active Drugs in myeloma with mechanism of action
Vincent Rajkumar shared a post on X: "Updated Active Drugs in myeloma with mechanism of…
Aug 12, 2024, 07:28 | Dialogues
Immunotherapy in Soft Tissue - 5 min Sarcoma Talk #6 with Sandra D'Angelo
In the new episode of "5 Minute Sarcoma Talk", Dr. Shushan Hovsepyan, the Editor-in-Chief of…
Aug 12, 2024, 01:35 | Blog
Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors
Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post by Ghayas Issa, Leukemia Physician at MD…
Aug 11, 2024, 12:39 | Blog
Ryan Locke: New ARPA-H funding opportunity in cancer screening 
Ryan Locke, Associate at Booz Allen Hamilton, posted on LinkedIn: "New ARPA-H funding opportunity in…
Aug 11, 2024, 12:09 | Insight
Weekly digest breakthroughs in cancer treatment, chemistry, and more by The Babak Lab
Maria Babak shared a post by The Babak Lab, on LinkedIn adding: “Let's recap on…
Aug 10, 2024, 11:58 | Insight
Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…
Aug 10, 2024, 11:10 | Insight
Shahrin Ahmed: Multiple myeloma treatment with Darzalex Faspro has been approved by the FDA
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: "Multiple…
Aug 10, 2024, 08:21 | Blog
Susan Pandya: The beginning of a new era for patients living with grade 2 IDH-mutant glioma
Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier,…
Aug 8, 2024, 12:35 | Blog
Miguel Bronchud: Liquid biopsy to detect early breast cancers
Miguel Bronchud, Co-Founder and Advisory Board at Regenerative Medicine Solutions, shared a post on LinkedIn,…
Aug 6, 2024, 16:11 | Insight
Daniel Peeper: Therapeutic approaches combined with PD1 axis blockade to provide synergistic clinical benefit
Daniel Peeper, Head of the Division of Molecular Oncology and Immunology at the Netherlands Cancer…
Aug 6, 2024, 11:47 | Drugs
FDA Grants Accelerated Approval to Afamitresgene Autoleucel (TECELRA) for Treating Advanced Synovial Sarcoma
On August 2, 2024, the FDA made history by granting accelerated approval to afamitresgene autoleucel…
Aug 5, 2024, 10:21 | Insight
Highlighting Key Voices in Sarcoma: OncoDaily’s Influencers for Awareness Month
On the occasion of July’s Sarcoma Awareness Month, OncoDaily recently put out a list of the…
Aug 5, 2024, 10:09 | Blog
Miguel Bronchud: Breast cancer screening - still with 'evolving guidelines'?
Miguel Bronchud, Co-Founder and Advisory Board at Regenerative Medicine Solutions, shared a post on LinkedIn: "Breast…
Aug 5, 2024, 09:17 | Insight
Yuji Uehara: Financial reimbursement boosts trial access, but ethical and legal hurdles remain
Yuji Uehara, Medical Oncologist at National Cancer Center Hospital East, Komagome Hospital, shared a post…
Aug 5, 2024, 04:49 | Drugs
Maria Babak: Key highlight from The Babak Lab on FDA Approval for Adagrasib
Maria Babak shared a post by The Babak Lab on LinkedIn: "This FDA approval represents…
Aug 4, 2024, 11:30 | Blog
Vincent Rajkumar reflects on FDA approval of Dara-VRd for newly diagnosed myeloma
Vincent Rajkumar shared a post on X: "FDA approves Dara-VRd for newly diagnosed myeloma. Quads…
Aug 4, 2024, 10:45 | Drugs
Vivek Subbiah: FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma
Vivek Subbiah shared a post on LinkedIn: "It's Friday and we have another FDA approval. FDA…
Aug 3, 2024, 12:57 | Blog
Bishal Gyawali: Revolving door between the regulators and the industry
Bishal Gyawali shared a post on X: "Revolving door between the regulators and the industry,…
Aug 3, 2024, 11:42 | Blog
Ishwaria Subbiah: Privileged to present at the July 1 Rounds of the FDA Oncology Center of Excellence
Ishwaria Subbiah shared a post on LinkedIn: "That's a wrap! July 2024 took me to…
Aug 3, 2024, 10:13 | Drugs
Harpreet Singh: ODAC vote marks a pivotal moment in oncology drug development
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared on LinkedIn: "The recent FDA…
Aug 2, 2024, 09:31 | Dialogues
Chinese Cancer Drug Set to Transform Global Market: Glecirasib | Most Promising Cancer Drugs 2024
In this exclusive interview with Dr. Andrea Wang-Gillam, we discuss the revolutionary potential of Glecirasib…
Aug 2, 2024, 05:24 | Insight
NCI Cancer Currents Blog about FDA's recent approvals of self-collection devices for HPV
NCI Division of Cancer Prevention shared on LinkedIn: “Check out the latest National Cancer Institute…
Aug 2, 2024, 04:39 | Insight
Four key solutions to address barriers for decentralizing trials to improve patient access
Archana Sah, Judge and Mentor at CancerX Moonshot, shared a paper by Ramya Thota et…
Jul 31, 2024, 14:18 | Blog
Formycon announced start of clinical phase III trial for Keytruda biosimilar candidate FYB206
Formycon AG announced that the first patient has been enrolled in the Phase III clinical…
Jul 31, 2024, 03:40 | Blog
Applications for the FDA-AACR Oncology Educational Fellowship are still open
AACR (American Association for Cancer Research) shared a post on LinkedIn: ''The FDA-AACR Oncology Educational…
Jul 30, 2024, 13:23 | Insight
Treatment of CML in pregnant patients and patients who are breastfeeding
FDA Oncology shared on X: An expert panel convened by FDA provides perspectives on drug…
Jul 29, 2024, 21:01 | Blog
Wafik S. El-Deiry: My own experience with quinacrine
Wafik S. El-Deiry shared a post on X: ''Here is my own experience with quinacrine…
Jul 29, 2024, 16:27 | Insight
Amol Akhade: It is time to take care of "missing third arm of the trial" syndrome
Amol Akhade shared his remarks on a study by Helen J Ross et al on…
Jul 29, 2024, 06:48 | Drugs
ODAC reviewed IMFINZI for treatment of resectable NSCLC based on AEGEAN Phase III trial results
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post on…
Jul 28, 2024, 14:38 | Drugs
Elad Sharon: Contribution of effect is an under appreciated and essential part of drug development
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared a post by FDA Oncology…
Jul 28, 2024, 13:07 | Blog
Scott Gottlieb: Congress must adopt a more modern policy scheme for advancing medical AI
Scott Gottlieb, Partner at New Enterprise Associates, shared a post on LinkedIn: "Congress must adopt…
Jul 27, 2024, 14:14 | Opinion
David Gandara: ODAC for the AEGEAN perioperative trial
David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on…
Jul 26, 2024, 06:54 | Insight
Discussions around updated OS data from Aegean Trial
AEGEAN trial is a phase 3 trial that tested the combination of perioperative durvalumab, a…
Jul 25, 2024, 08:43 | Blog
David Fajgenbaum: Pioneering the use of agent-based models to revolutionize drug repurposing
David Fajgenbaum shared on X: ''At Every Cure, we are pioneering the use of agent-based…
Jul 24, 2024, 14:40 | Blog
Bernard Fox: 100 New Cancer Immunotherapy drug approvals in the next decade
Bernard Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn: "100 New Cancer Immunotherapy drug approvals…
Jul 24, 2024, 14:01 | Blog
Eleni Taoula: Complex global regulatory landscape for ADCs
Eleni Taoula, Associate Professor at The University of Nicosia Medical School, shared on LinkedIn:  "ADC drugs…
Jul 24, 2024, 07:43 | Blog
Considerations to improve collection and analysis of overall survival data in oncology clinical trials - AACR
AACR (American Association for Cancer Research) shared a post on LinkedIn: ''A new perspective paper…
Jul 23, 2024, 15:52 | Drugs
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
In the rapidly evolving field of oncology, we are witnessing remarkable advancements in various treatment…
Jul 20, 2024, 21:26 | Blog
David Fajgenbaum: Santa Claus theory of civilization
David Fajgenbaum, Associate Professor of Medicine at University of Pennsylvania School of Medicine, shared on…
Jul 19, 2024, 22:55 | Blog
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X: "What after Osimertinib…
Jul 19, 2024, 22:19 | Insight
Yüksel Ürün: Congratulations all new participants of the ASCO Leadership Development Program!
Yüksel Ürün shared a post by Miriam Knoll, on X, adding: "Congratulations to you and…
Jul 19, 2024, 11:39 | Blog
Oncology Nursing Society - Oncology Nurse’s Guide to the FDA Cancer Drug Approval Process
Oncology Nursing Society shared on LinkedIn: "Every nurse plays a crucial role in ensuring patient safety…
Jul 19, 2024, 10:31 | Blog
2024 DIA Singapore Annual Conference Session on New Regulatory Fields and Trends
Finny Liu, APAC Regional Regulatory Policy Lead, PDR at Roche Singapore, shared on LinkedIn: "2024…
Jul 19, 2024, 00:37 | Societies
Stephen Williams on his experience in the FDA-AACR Oncology Educational Fellowship program
The American Association for Cancer Research shared on LinkedIn: "“The FDA-AACR fellowship undoubtedly enhanced my…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 18, 2024, 10:05 | Insight
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Breaking News: EMA Joins FDA in Approving Osimerintib with Chemotherapy as a New 1st-Line Treatment…
Jul 16, 2024, 20:16 | Insight
Top 5 articles of the week – Cancer Network
Cancer Network shared on X/Twitter: ''View our top 5 articles of the week: FDA Approves…
Jul 16, 2024, 20:12 | Drugs
Miguel Bronchud: How to make a new anti cancer drug in your kitchen?
Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared a post on LinkedIn: “How to make…
Jul 16, 2024, 14:07 | Blog
From Awareness to Action: Tackling the Rising Burden of Common Chronic Diseases
"Since graduating from medical school in 1978, I’ve seen medicine and healthcare change in unimaginable…
Jul 14, 2024, 22:08 | Blog
Ivan R. Gonzalez: Project Orbis: A global initiative to accelerate the review of cancer drugs in the US, Canada, and the UK
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post…
Jul 14, 2024, 13:44 | Dialogues
Amazing Results! President Lynn M. Schuchter on ASCO 2024
This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site.…
Jul 13, 2024, 15:19 | Blog
Kristina Jenei: Are countries harmonizing up or down?
Dario Trapani, Medical Oncologist at European Institute of Oncology, shared a post by Kristina Jenei, Associate…
Jul 13, 2024, 02:24 | Insight
Pamela Basto is experienced as a participant in the FDA-AACR Oncology Educational Fellowship program - AACR
American Association for Cancer Research (AACR) made the following post on LinkedIn: “‘The FDA-AACR program…
Jul 10, 2024, 15:08 | Insight
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
On the basis of its positive clinical studies Mainz Biomed has now defined the final…
Jul 10, 2024, 10:01 | Blog
Scott Armstrong has been named senior vice president for Drug Discovery and chief research strategy officer at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on LinkedIn: "Scott Armstrong has been named senior vice president for Drug Discovery…
Jul 9, 2024, 14:42 | Drugs
Vincent Rajkumar: FDA approval doesn’t necessarily mean standard of care
Vincent Rajkumar shared on X: "FDA approval doesn’t necessarily mean standard of care. For example,…
Jul 9, 2024, 08:38 | Insight
Maria Babak: FDA approval to lifileucel for advanced melanoma offers hope to those with limited options
Maria Babak shared a post by The Babak Lab on LinkedIn, adding: “This is a…
Jul 9, 2024, 07:52 | Insight
Kimryn Rathmell: Big announcement from FDA regarding diversity in clinical trials
Kimryn Rathmell shared on X: “Big announcement from FDA regarding diversity in clinical trials. U.S. FDA…
Jul 8, 2024, 17:25 | Drugs
Fadi Haddad: US FDA approval of BLINCYTO in patients with ALL
Fadi Haddad, Assistant Professor at the Leukemia Department at the MD Anderson Cancer Center shared…
Jul 8, 2024, 04:52 | Insight
Spotlight on Alveolar soft part sarcoma - NCI
National Cancer Institute (NCI) shared a post on LinkedIn: "Alveolar soft part sarcoma (ASPS) is…
Jul 7, 2024, 04:58 | Insight
Cancer cabinet community conversation on July 11 - FDA Oncology
FDA Oncology shared on X: “Join us for a special Cancer Cabinet Community Conversation on…
Jul 7, 2024, 02:53 | Blog
Game changer for hepatitis C diagnosis - NCI Division of Cancer Prevention
NCI Division of Cancer Prevention shared a post on LinkedIn: "Cancer prevention can sometimes mean…
Jul 6, 2024, 15:02 | Blog
FDA-AACR Oncology Educational Fellowship's impact on participants
American Association for Cancer Research shared a post on LinkedIn: “An article in Clinical Cancer…
Jul 4, 2024, 08:41 | Blog
Julie McCrossin: Exciting clinical innovation - FDA approved Adaptive Proton Therapy
Julie McCrossin, Broadcaster, Cancer Survivor and Community Educator, shared a post in LinkedIn:  . "How…
Jul 3, 2024, 06:28 | Blog
Yelak Biru: Is myeloma science and clinical progress fast or slow?
Yelak Biru, President and CEO at the International Myeloma Foundation, shared on X: "Is myeloma…
Jul 3, 2024, 04:18 | Blog
FDA and WHOSTP discuss increasing clinical trials access and lowering barriers to participation
FDA Oncology shared on X: “FDA Oncology Center's Paul Kluetz, Rick Pazdur, Donna Rivera attended…
Jul 3, 2024, 01:43 | Insight
FDA's ongoing efforts to promote broad and inclusive eligibility criteria in clinical trials - Friends of Cancer Research
American Society of Clinical Oncology (ASCO) shared a post by Friends of Cancer Research on…
Jul 2, 2024, 22:59 | Blog
Society for Immunotherapy of Cancer's Clinical Practice Guidelines to improve patient outcomes
Society for Immunotherapy of Cancer shared on LinkedIn: "Implement the latest FDA-approved cancer immunotherapies into practice…
Jul 2, 2024, 09:30 | Blog
Aman Khera: The FDA DAP updated draft guidance is out
Aman Khera, Vice President of Regulatory Science and Innovation at Worldwide Clinical Trials, shared on LinkedIn:…
Jul 1, 2024, 15:15 | Blog
Cesar Perez: Increasing the Impact of Immunotherapy
Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and…
Jul 1, 2024, 15:09 | Blog
Yüksel Ürün: Did you know the FDA approved cancer drugs target fewer than 200 proteins?
Yüksel Ürün shared a post on X: “Did you know the FDA approved cancer drugs…
All: 286 Posts: 1 - 100
Special Coverage